A federal judge has dismissed all claims against GlaxoSmithKline in the Wellbutrin XL antitrust litigation in which the pharmaceutical giant was accused of delaying the entry of generic versions of the antidepressant medication to market by entering into illegal agreements with generic drug makers to settle patent infringement lawsuits.
Read the original post:
Wellbutrin Antitrust Cases Against GSK Dismissed
